| Assessment Status | Rapid Review Complete |
| HTA ID | 21051 |
| Drug | Mometasone furoate plus olopatadine |
| Brand | Ryaltris® |
| Indication | Is indicated for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis in adults and adolescents aged 12 years and older. |
| Assessment Process | |
| Rapid review commissioned | 15/11/2021 |
| Rapid review completed | 22/12/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that mometasone furoate plus olopatadine (Ryaltris®) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement May 2022.
